Glembatumumab vedotin is well tolerated in heavily pretreated patients with breast cancer and may be effective in some patients with glycoprotein NMB (gpNMB)-expressing breast cancer, a new study published online early in the Journal of Clinical Oncology has shown.

For the phase II study, researchers enrolled 124 patients with refractory breast cancer that overexpressed gpNMB, a negative prognostic marker.

Participants were randomly assigned 1:1 to receive glembatumumab vedotin or investigator’s choice chemotherapy.

Continue Reading

Results showed that the overall response rate was 6% for the glembatumumab vedotin group versus 7% for the chemotherapy group.

RELATED: Bevacizumab Window Period May Be Effective for Brain Metastases of Breast Cancer

Unplanned analysis showed an objective response rate of 18% in the glembatumumab vedotin group versus 0% in the chemotherapy group in patients with triple-negative breast cancer (TNBC).

In those with gpNMB-overexpressing TNBC, the objective response rates were 40% and 0% in the glembatumumab and chemotherapy groups, respectively.

Preliminary findings were presented at the 36th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas in 2013.


  1. Yardley DA, Weaver R, Melisko ME, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced-glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.56.2959.